Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oulanti Weikang Tablet in functional dyspepsia (PDS, qi stagnation)
CTR20191090Phase 2Active
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Jun 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Oulanti Weikang Tablet in functional dyspepsia (FD), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Started Jun 2019; status: active.
02
Drugs
Oulanti Weikang Tablet
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on CTR20191090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191090.